{"id":363841,"date":"2025-08-31T11:01:01","date_gmt":"2025-08-31T11:01:01","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-enliven-therapeutics\/"},"modified":"2025-08-31T11:01:01","modified_gmt":"2025-08-31T11:01:01","slug":"how-to-buy-enliven-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334036,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-363841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics (ELVN), ph\u00e2n t\u00edch hi\u1ec7u su\u1ea5t n\u0103m 2025 v\u00e0 hi\u1ec3u c\u00e1c r\u1ee7i ro c\u0169ng nh\u01b0 c\u01a1 h\u1ed9i \u0111\u1ea7u t\u01b0 trong c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u00e0y.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics (ELVN), ph\u00e2n t\u00edch hi\u1ec7u su\u1ea5t n\u0103m 2025 v\u00e0 hi\u1ec3u c\u00e1c r\u1ee7i ro c\u0169ng nh\u01b0 c\u01a1 h\u1ed9i \u0111\u1ea7u t\u01b0 trong c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u00e0y."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ung th\u01b0 \u0111\u1ed9t ph\u00e1 ti\u1ebfp theo? Enliven Therapeutics \u0111\u1ea1i di\u1ec7n cho bi\u00ean gi\u1edbi th\u00fa v\u1ecb c\u1ee7a ung th\u01b0 h\u1ecdc ch\u00ednh x\u00e1c \u2014 n\u01a1i khoa h\u1ecdc ti\u00ean ti\u1ebfn g\u1eb7p g\u1ee1 nh\u1eefng k\u1ebft qu\u1ea3 thay \u0111\u1ed5i cu\u1ed9c s\u1ed1ng cho b\u1ec7nh nh\u00e2n. C\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u00e0y c\u00f3 th\u1ec3 c\u00e1ch m\u1ea1ng h\u00f3a c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb b\u1ec7nh b\u1ea1ch c\u1ea7u t\u1ee7y m\u1ea1n t\u00ednh, t\u1ea1o n\u00ean c\u01a1 h\u1ed9i h\u1ea5p d\u1eabn cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 t\u1ea7m nh\u00ecn xa.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ung th\u01b0 \u0111\u1ed9t ph\u00e1 ti\u1ebfp theo? Enliven Therapeutics \u0111\u1ea1i di\u1ec7n cho bi\u00ean gi\u1edbi th\u00fa v\u1ecb c\u1ee7a ung th\u01b0 h\u1ecdc ch\u00ednh x\u00e1c \u2014 n\u01a1i khoa h\u1ecdc ti\u00ean ti\u1ebfn g\u1eb7p g\u1ee1 nh\u1eefng k\u1ebft qu\u1ea3 thay \u0111\u1ed5i cu\u1ed9c s\u1ed1ng cho b\u1ec7nh nh\u00e2n. C\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u00e0y c\u00f3 th\u1ec3 c\u00e1ch m\u1ea1ng h\u00f3a c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb b\u1ec7nh b\u1ea1ch c\u1ea7u t\u1ee7y m\u1ea1n t\u00ednh, t\u1ea1o n\u00ean c\u01a1 h\u1ed9i h\u1ea5p d\u1eabn cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 t\u1ea7m nh\u00ecn xa."},"body_html":"<h2>\ud83d\udcc8 Ph\u00e2n T\u00edch C\u1ed5 Phi\u1ebfu Enliven Therapeutics: T\u00ecnh Tr\u1ea1ng Hi\u1ec7n T\u1ea1i v\u00e0 Ti\u1ec1m N\u0103ng T\u01b0\u01a1ng Lai<\/h2> <p><strong>T\u00ednh \u0111\u1ebfn ng\u00e0y 31 th\u00e1ng 8 n\u0103m 2025, c\u1ed5 phi\u1ebfu Enliven Therapeutics (ELVN) giao d\u1ecbch \u1edf m\u1ee9c 20,68 USD\/c\u1ed5 phi\u1ebfu<\/strong> tr\u00ean s\u00e0n NASDAQ. C\u1ed5 phi\u1ebfu \u0111\u00e3 tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 trong su\u1ed1t n\u0103m 2025, giao d\u1ecbch trong ph\u1ea1m vi 52 tu\u1ea7n t\u1eeb 13,30 USD \u0111\u1ebfn 30,03 USD, th\u1ec3 hi\u1ec7n c\u1ea3 r\u1ee7i ro v\u00e0 c\u01a1 h\u1ed9i l\u1edbn cho nh\u00e0 \u0111\u1ea7u t\u01b0.<\/p> <p>H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch: <strong>Ng\u00e0y 12 th\u00e1ng 11 n\u0103m 2025<\/strong> l\u00e0 ng\u00e0y c\u1ef1c k\u1ef3 quan tr\u1ecdng \u0111\u1ed1i v\u1edbi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ELVN. \u0110\u00e2y l\u00e0 th\u1eddi \u0111i\u1ec3m c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn qu\u00fd 3, v\u00e0 c\u00e1c m\u00f4 h\u00ecnh l\u1ecbch s\u1eed cho th\u1ea5y \u0111i\u1ec1u n\u00e0y c\u00f3 th\u1ec3 k\u00edch ho\u1ea1t nh\u1eefng bi\u1ebfn \u0111\u1ed9ng gi\u00e1 l\u1edbn.<\/p> <h3>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng L\u1ee3i Nhu\u1eadn L\u1ecbch S\u1eed<\/h3> <p>Xem x\u00e9t hi\u1ec7u su\u1ea5t g\u1ea7n \u0111\u00e2y quanh c\u00e1c s\u1ef1 ki\u1ec7n ch\u00ednh cung c\u1ea5p nh\u1eefng hi\u1ec3u bi\u1ebft gi\u00e1 tr\u1ecb:<\/p> <p><strong>Ng\u00e0y 13 th\u00e1ng 8 n\u0103m 2025<\/strong> - C\u00f4ng b\u1ed1 l\u1ee3i nhu\u1eadn qu\u00fd 2: ELVN b\u00e1o c\u00e1o k\u1ebft qu\u1ea3 t\u1ed1t h\u01a1n k\u1ef3 v\u1ecdng v\u1edbi EPS l\u00e0 -0,49 USD so v\u1edbi \u01b0\u1edbc t\u00ednh \u0111\u1ed3ng thu\u1eadn -0,53 USD (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/ELVN\/earnings\/\">D\u1eef li\u1ec7u L\u1ee3i Nhu\u1eadn MarketBeat<\/a>). B\u1ea5t ng\u1edd t\u00edch c\u1ef1c n\u00e0y cho th\u1ea5y kh\u1ea3 n\u0103ng qu\u1ea3n l\u00fd chi ph\u00ed trong khi ti\u1ebfn tri\u1ec3n c\u00e1c ch\u01b0\u01a1ng tr\u00ecnh l\u00e2m s\u00e0ng c\u1ee7a c\u00f4ng ty.<\/p> <p>Ph\u1ea3n \u1ee9ng c\u1ee7a c\u1ed5 phi\u1ebfu v\u1edbi tin t\u1ee9c n\u00e0y r\u1ea5t \u0111\u00e1ng ch\u00fa \u00fd \u2014 trong khi nhi\u1ec1u c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ch\u1ee9ng ki\u1ebfn bi\u1ebfn \u0111\u1ed9ng m\u1ea1nh v\u00e0o ng\u00e0y c\u00f4ng b\u1ed1 l\u1ee3i nhu\u1eadn, ELVN th\u1ec3 hi\u1ec7n s\u1ef1 \u1ed5n \u0111\u1ecbnh t\u01b0\u01a1ng \u0111\u1ed1i, cho th\u1ea5y c\u01a1 s\u1edf nh\u00e0 \u0111\u1ea7u t\u01b0 tr\u01b0\u1edfng th\u00e0nh hi\u1ec3u r\u00f5 v\u1ec1 ti\u1ebfn tr\u00ecnh ph\u00e1t tri\u1ec3n d\u00e0i h\u1ea1n.<\/p> <h3>H\u00e0nh Tr\u00ecnh Gi\u00e1 S\u00e1u Th\u00e1ng (Th\u00e1ng 3 - Th\u00e1ng 8 n\u0103m 2025)<\/h3> <p>ELVN \u0111\u00e3 v\u01b0\u1ee3t qua m\u1ed9t con \u0111\u01b0\u1eddng \u0111\u1ea7y th\u1eed th\u00e1ch nh\u01b0ng \u0111\u1ea7y h\u1ee9a h\u1eb9n trong s\u00e1u th\u00e1ng qua:<\/p> <table> <thead> <tr><th>Th\u00e1ng<\/th><th>S\u1ef1 Ki\u1ec7n Ch\u00ednh<\/th><th>Ph\u1ea1m Vi Gi\u00e1<\/th><th>Xu H\u01b0\u1edbng<\/th><\/tr> <\/thead> <tbody> <tr><td>Th\u00e1ng 3 n\u0103m 2025<\/td><td>L\u1ea1c quan d\u1eef li\u1ec7u l\u00e2m s\u00e0ng ban \u0111\u1ea7u<\/td><td>25-28 USD<\/td><td>\u2197\ufe0f \u0110\u00e0 t\u0103ng<\/td><\/tr> <tr><td>Th\u00e1ng 4 n\u0103m 2025<\/td><td>\u00c1p l\u1ef1c r\u1ed9ng h\u01a1n t\u1eeb ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/td><td>18-22 USD<\/td><td>\u2198\ufe0f \u0110i\u1ec1u ch\u1ec9nh to\u00e0n ng\u00e0nh<\/td><\/tr> <tr><td>Th\u00e1ng 5 n\u0103m 2025<\/td><td>Chu\u1ea9n b\u1ecb thuy\u1ebft tr\u00ecnh h\u1ed9i ngh\u1ecb<\/td><td>20-24 USD<\/td><td>\u27a1\ufe0f T\u00edch l\u0169y<\/td><\/tr> <tr><td>Th\u00e1ng 6 n\u0103m 2025<\/td><td>C\u00f4ng b\u1ed1 d\u1eef li\u1ec7u t\u1ea1i H\u1ed9i ngh\u1ecb EHA<\/td><td>22-27 USD<\/td><td>\u2197\ufe0f Ph\u1ea3n \u1ee9ng t\u00edch c\u1ef1c m\u1ea1nh m\u1ebd<\/td><\/tr> <tr><td>Th\u00e1ng 7 n\u0103m 2025<\/td><td>Ch\u1ed1t l\u1eddi sau h\u1ed9i ngh\u1ecb<\/td><td>19-23 USD<\/td><td>\u2198\ufe0f \u0110i\u1ec1u ch\u1ec9nh l\u00e0nh m\u1ea1nh<\/td><\/tr> <tr><td>Th\u00e1ng 8 n\u0103m 2025<\/td><td>L\u1ee3i nhu\u1eadn qu\u00fd 2 v\u00e0 h\u1ebft h\u1ea1n th\u1eddi gian kh\u00f3a c\u1ed5 phi\u1ebfu<\/td><td>20-21 USD<\/td><td>\u27a1\ufe0f \u1ed4n \u0111\u1ecbnh gi\u1eefa c\u00e1c s\u1ef1 ki\u1ec7n<\/td><\/tr> <\/tbody> <\/table> <p><strong>T\u0103ng 11% c\u1ed5 phi\u1ebfu sau d\u1eef li\u1ec7u t\u00edch c\u1ef1c ELVN-001<\/strong> t\u1ea1i h\u1ed9i ngh\u1ecb Hi\u1ec7p h\u1ed9i Huy\u1ebft h\u1ecdc Ch\u00e2u \u00c2u (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">B\u00e1o c\u00e1o Oncology Pipeline<\/a>) cho th\u1ea5y c\u00e1c c\u1ed9t m\u1ed1c l\u00e2m s\u00e0ng th\u00fac \u0111\u1ea9y \u0111\u1ecbnh gi\u00e1 trong ng\u00e0nh n\u00e0y nh\u01b0 th\u1ebf n\u00e0o.<\/p> [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2> <p>D\u1ef1a tr\u00ean \u0111\u1ed3ng thu\u1eadn hi\u1ec7n t\u1ea1i c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u00e0 ti\u1ebfn tri\u1ec3n l\u00e2m s\u00e0ng, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 mong \u0111\u1ee3i:<\/p> <p><strong>M\u1ee5c ti\u00eau cu\u1ed1i n\u0103m 2025: 25-30 USD<\/strong> - D\u00f2ng d\u1eef li\u1ec7u t\u00edch c\u1ef1c ti\u1ebfp t\u1ee5c t\u1eeb c\u00e1c th\u1eed nghi\u1ec7m \u0111ang di\u1ec5n ra c\u00f3 th\u1ec3 \u0111\u1ea9y ELVN v\u1ec1 ph\u00eda cu\u1ed1i tr\u00ean c\u1ee7a ph\u1ea1m vi giao d\u1ecbch g\u1ea7n \u0111\u00e2y. B\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn th\u00e1ng 11 s\u1ebd r\u1ea5t quan tr\u1ecdng \u0111\u1ec3 thi\u1ebft l\u1eadp \u0111\u00e0 t\u0103ng cu\u1ed1i n\u0103m.<\/p> <p><strong>D\u1ef1 b\u00e1o n\u0103m 2026: 35-45 USD<\/strong> - N\u1ebfu c\u00e1c th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 2 b\u1eaft \u0111\u1ea7u th\u00e0nh c\u00f4ng v\u00e0 c\u00e1c con \u0111\u01b0\u1eddng ph\u00e1p l\u00fd \u0111\u01b0\u1ee3c th\u00f4ng qua, ELVN c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c \u0111\u1ecbnh gi\u00e1 l\u1ea1i \u0111\u00e1ng k\u1ec3 khi th\u1ecb tr\u01b0\u1eddng \u0111\u00e1nh gi\u00e1 r\u1ee7i ro l\u00e2m s\u00e0ng gi\u1ea3m.<\/p> <p><strong>D\u1ef1 \u0111o\u00e1n n\u0103m 2028: 50-70 USD<\/strong> - C\u00e1c \u0111\u1ec7 tr\u00ecnh ph\u00e1p l\u00fd ti\u1ec1m n\u0103ng v\u00e0 th\u1ea3o lu\u1eadn h\u1ee3p t\u00e1c c\u00f3 th\u1ec3 th\u00fac \u0111\u1ea9y \u0111\u1ecbnh gi\u00e1 h\u01b0\u1edbng t\u1edbi c\u00e1c m\u1ee5c ti\u00eau gi\u00e1 c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch tr\u00ean 50 USD.<\/p> <p><strong>T\u1ea7m nh\u00ecn n\u0103m 2030: 80-100+ USD<\/strong> - Th\u01b0\u01a1ng m\u1ea1i h\u00f3a th\u00e0nh c\u00f4ng v\u00e0 th\u00e2m nh\u1eadp th\u1ecb tr\u01b0\u1eddng c\u00f3 th\u1ec3 thi\u1ebft l\u1eadp ELVN nh\u01b0 m\u1ed9t c\u00f4ng ty t\u1ef7 \u0111\u00f4, m\u1eb7c d\u00f9 \u0111i\u1ec1u n\u00e0y ho\u00e0n to\u00e0n ph\u1ee5 thu\u1ed9c v\u00e0o th\u00e0nh c\u00f4ng l\u00e2m s\u00e0ng v\u00e0 ph\u00ea duy\u1ec7t ph\u00e1p l\u00fd.<\/p> <p><strong>K\u1ebft lu\u1eadn: MUA M\u1ea0NH<\/strong> d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 ch\u1ecbu r\u1ee7i ro v\u1edbi t\u1ea7m nh\u00ecn 3-5 n\u0103m. \u0110\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 trung b\u00ecnh 41,20 USD (<a href=\"https:\/\/stockanalysis.com\/stocks\/elvn\/forecast\/\">Ph\u00e2n t\u00edch C\u1ed5 phi\u1ebfu<\/a>) \u0111\u1ea1i di\u1ec7n cho ti\u1ec1m n\u0103ng t\u0103ng h\u01a1n 100% so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i.<\/p> <h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2> <h3>R\u1ee7i Ro M\u1ecdi Nh\u00e0 \u0110\u1ea7u T\u01b0 Ph\u1ea3i C\u00e2n Nh\u1eafc<\/h3> <ul> <li><strong>R\u1ee7i ro Th\u1ea5t b\u1ea1i Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng<\/strong> - Kho\u1ea3ng 60% c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc tr\u1ea3i qua s\u1ee5t gi\u1ea3m tr\u00ean 50% khi c\u00f3 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m ti\u00eau c\u1ef1c. To\u00e0n b\u1ed9 \u0111\u1ecbnh gi\u00e1 c\u1ee7a ELVN ph\u1ee5 thu\u1ed9c v\u00e0o th\u00e0nh c\u00f4ng c\u1ee7a ELVN-001.<\/li> <li><strong>Tr\u00ec ho\u00e3n Ph\u00ea duy\u1ec7t Ph\u00e1p l\u00fd<\/strong> - Qu\u00e1 tr\u00ecnh xem x\u00e9t c\u1ee7a FDA c\u00f3 th\u1ec3 k\u00e9o d\u00e0i 6-12 th\u00e1ng b\u1ea5t ng\u1edd, l\u00e0m \u0111\u00f3ng b\u0103ng l\u1ee3i nhu\u1eadn ti\u1ec1m n\u0103ng v\u00e0 t\u1ea1o ra s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn.<\/li> <li><strong>Lo ng\u1ea1i v\u1ec1 D\u00f2ng ti\u1ec1n Ti\u00eau hao<\/strong> - M\u1eb7c d\u00f9 v\u1eeba huy \u0111\u1ed9ng \u0111\u01b0\u1ee3c 200 tri\u1ec7u USD (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">Chi ti\u1ebft Huy \u0111\u1ed9ng V\u1ed1n<\/a>), d\u00f2ng ti\u1ec1n \u00e2m 52,7 tri\u1ec7u USD c\u1ee7a c\u00f4ng ty c\u1ea7n \u0111\u01b0\u1ee3c theo d\u00f5i ch\u1eb7t ch\u1ebd.<\/li> <li><strong>Bi\u1ebfn \u0111\u1ed9ng Cao<\/strong> - V\u1edbi bi\u1ebfn \u0111\u1ed9ng trung b\u00ecnh h\u00e0ng ng\u00e0y 4,37% v\u00e0 t\u1ef7 l\u1ec7 s\u1edf h\u1eefu t\u1ed5 ch\u1ee9c 95%, c\u00e1c giao d\u1ecbch l\u1edbn c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng m\u1ea1nh \u0111\u1ebfn gi\u00e1 c\u1ed5 phi\u1ebfu.<\/li> <\/ul> <h3>T\u00edn Hi\u1ec7u Xanh Cho \u0110\u1ea7u T\u01b0 N\u0103m 2025<\/h3> <ul> <li><strong>D\u1eef li\u1ec7u L\u00e2m s\u00e0ng \u0110\u1ed9t ph\u00e1<\/strong> - ELVN-001 cho th\u1ea5y t\u1ef7 l\u1ec7 \u0111\u00e1p \u1ee9ng ph\u00e2n t\u1eed ch\u00ednh 47% \u1edf b\u1ec7nh nh\u00e2n CML \u0111\u00e3 \u0111i\u1ec1u tr\u1ecb nhi\u1ec1u l\u1ea7n, c\u1ea1nh tranh v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb nh\u01b0 Scemblix c\u1ee7a Novartis.<\/li> <li><strong>Huy \u0111\u1ed9ng V\u1ed1n Th\u00e0nh c\u00f4ng<\/strong> - Vi\u1ec7c m\u1edf r\u1ed9ng v\u1ed1n 200 tri\u1ec7u USD cung c\u1ea5p ngu\u1ed3n l\u1ef1c \u0111\u1ebfn n\u0103m 2029, gi\u1ea3m b\u1edbt lo ng\u1ea1i pha lo\u00e3ng g\u1ea7n h\u1ea1n.<\/li> <li><strong>Ni\u1ec1m Tin c\u1ee7a Nh\u00e0 Ph\u00e2n t\u00edch<\/strong> - T\u1ea5t c\u1ea3 5 nh\u00e0 ph\u00e2n t\u00edch theo d\u00f5i duy tr\u00ec \u0111\u00e1nh gi\u00e1 \"Mua M\u1ea1nh\" v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 l\u00ean \u0111\u1ebfn 52 USD.<\/li> <li><strong>Nhu c\u1ea7u Th\u1ecb tr\u01b0\u1eddng<\/strong> - CML l\u00e0 th\u1ecb tr\u01b0\u1eddng h\u01a1n 7 t\u1ef7 USD v\u1edbi nhu c\u1ea7u ch\u01b0a \u0111\u01b0\u1ee3c \u0111\u00e1p \u1ee9ng l\u1edbn \u1edf b\u1ec7nh nh\u00e2n kh\u00e1ng \u0111i\u1ec1u tr\u1ecb.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2> <ol> <li><strong>B\u1eaft \u0111\u1ea7u Nh\u1ecf<\/strong> - Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 5% danh m\u1ee5c cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ee7i ro cao nh\u01b0 ELVN. Ph\u1ea7n th\u01b0\u1edfng ti\u1ec1m n\u0103ng l\u1edbn, nh\u01b0ng r\u1ee7i ro c\u0169ng kh\u00f4ng nh\u1ecf.<\/li> <li><strong>Trung B\u00ecnh Gi\u00e1 Mua<\/strong> - Thay v\u00ec mua m\u1ed9t l\u1ea7n l\u1edbn, h\u00e3y c\u00e2n nh\u1eafc mua t\u1eebng ph\u1ea7n nh\u1ecf trong v\u00e0i tu\u1ea7n \u0111\u1ec3 trung b\u00ecnh gi\u00e1 v\u00e0o.<\/li> <li><strong>\u0110\u1eb7t C\u1ea3nh B\u00e1o cho Ng\u00e0y 12 Th\u00e1ng 11<\/strong> - \u0110\u00e1nh d\u1ea5u l\u1ecbch cho b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn qu\u00fd 3 v\u00e0 chu\u1ea9n b\u1ecb cho bi\u1ebfn \u0111\u1ed9ng c\u00f3 th\u1ec3 x\u1ea3y ra quanh s\u1ef1 ki\u1ec7n n\u00e0y.<\/li> <li><strong>Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc d\u00e0nh cho nh\u00e0 giao d\u1ecbch<\/strong>: \"\u0110\u1ea7u t\u01b0 v\u00e0o c\u00f4ng ngh\u1ec7 sinh h\u1ecdc gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2 th\u1eddi trung h\u1ecdc \u2014 90% l\u00e0 drama, 10% l\u00e0 ti\u1ebfn tri\u1ec3n th\u1ef1c s\u1ef1, nh\u01b0ng 10% \u0111\u00f3 c\u00f3 th\u1ec3 thay \u0111\u1ed5i cu\u1ed9c \u0111\u1eddi khi n\u00f3 th\u00e0nh c\u00f4ng!\"<\/li> <\/ol> <h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - T\u1eebng B\u01b0\u1edbc<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0110\u1ed9ng<\/th><th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ch\u1ecdn N\u1ec1n T\u1ea3ng Giao D\u1ecbch<\/td><td>Ch\u1ecdn nh\u00e0 m\u00f4i gi\u1edbi cung c\u1ea5p truy c\u1eadp NASDAQ v\u00e0 ph\u00ed c\u1ea1nh tranh cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/td><\/tr> <tr><td>2<\/td><td>Ho\u00e0n Th\u00e0nh N\u1ea1p Ti\u1ec1n T\u00e0i Kho\u1ea3n<\/td><td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i r\u1ee7i ro \u2014 ngay c\u1ea3 100 USD c\u0169ng c\u00f3 th\u1ec3 gi\u00fap b\u1ea1n b\u1eaft \u0111\u1ea7u<\/td><\/tr> <tr><td>3<\/td><td>T\u00ecm ki\u1ebfm \"ELVN\"<\/td><td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n ch\u00ednh x\u00e1c, kh\u00f4ng ch\u1ec9 t\u00ean c\u00f4ng ty<\/td><\/tr> <tr><td>4<\/td><td>Ch\u1ecdn Lo\u1ea1i L\u1ec7nh<\/td><td>S\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o thay v\u00ec l\u1ec7nh th\u1ecb tr\u01b0\u1eddng<\/td><\/tr> <tr><td>5<\/td><td>Xem l\u1ea1i v\u00e0 X\u00e1c nh\u1eadn<\/td><td>Ki\u1ec3m tra k\u1ef9 chi ti\u1ebft l\u1ec7nh v\u00e0 hi\u1ec3u c\u00e1c chi ph\u00ed hoa h\u1ed3ng<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Thu H\u00fat Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0 v\u1edbi c\u00e1c c\u00f4ng ty nh\u01b0 Enliven Therapeutics, Pocket Option cung c\u1ea5p nhi\u1ec1u l\u1ee3i th\u1ebf gi\u00fap vi\u1ec7c tham gia th\u1ecb tr\u01b0\u1eddng tr\u1edf n\u00ean d\u1ec5 d\u00e0ng h\u01a1n:<\/p> <ul> <li><strong>S\u1ed1 ti\u1ec1n g\u1eedi t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> - R\u00e0o c\u1ea3n c\u1ef1c th\u1ea5p n\u00e0y cho ph\u00e9p nh\u00e0 \u0111\u1ea7u t\u01b0 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u00e0 t\u00edch l\u0169y kinh nghi\u1ec7m m\u00e0 kh\u00f4ng c\u1ea7n cam k\u1ebft t\u00e0i ch\u00ednh l\u1edbn.<\/li> <li><strong>Quy tr\u00ecnh x\u00e1c minh nhanh ch\u00f3ng<\/strong> - Quy tr\u00ecnh KYC (Bi\u1ebft Kh\u00e1ch H\u00e0ng) ch\u1ec9 m\u1ea5t 1 ph\u00fat v\u1edbi b\u1ea5t k\u1ef3 gi\u1ea5y t\u1edd t\u00f9y th\u00e2n n\u00e0o, gi\u00fap b\u1ea1n c\u00f3 th\u1ec3 b\u1eaft \u0111\u1ea7u giao d\u1ecbch g\u1ea7n nh\u01b0 ngay l\u1eadp t\u1ee9c sau khi \u0111\u0103ng k\u00fd.<\/li> <li><strong>Nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> - V\u1edbi h\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n bao g\u1ed3m ti\u1ec1n \u0111i\u1ec7n t\u1eed, v\u00ed \u0111i\u1ec7n t\u1eed v\u00e0 c\u00e1c l\u1ef1a ch\u1ecdn ng\u00e2n h\u00e0ng truy\u1ec1n th\u1ed1ng, vi\u1ec7c ti\u1ebfp c\u1eadn l\u1ee3i nhu\u1eadn c\u1ee7a b\u1ea1n tr\u1edf n\u00ean thu\u1eadn ti\u1ec7n v\u00e0 linh ho\u1ea1t.<\/li> <\/ul> <p>Nh\u1eefng t\u00ednh n\u0103ng n\u00e0y l\u00e0m cho Pocket Option \u0111\u1eb7c bi\u1ec7t ph\u00f9 h\u1ee3p v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n th\u1eed s\u1ee9c v\u1edbi \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc m\u00e0 kh\u00f4ng b\u1ecb ph\u1ee9c t\u1ea1p hay chi ph\u00ed ban \u0111\u1ea7u cao.<\/p> <h2>\ud83c\udf0d Enliven Therapeutics n\u0103m 2025: Ti\u00ean Phong Ung Th\u01b0 H\u1ecdc Ch\u00ednh X\u00e1c<\/h2> <p>Enliven Therapeutics \u0111\u1ee9ng \u1edf v\u1ecb tr\u00ed ti\u00ean phong trong ung th\u01b0 h\u1ecdc ch\u00ednh x\u00e1c v\u1edbi c\u00e1ch ti\u1ebfp c\u1eadn t\u1eadp trung v\u00e0o ph\u00e1t tri\u1ec3n ch\u1ea5t \u1ee9c ch\u1ebf kinase. \u1ee8ng vi\u00ean h\u00e0ng \u0111\u1ea7u c\u1ee7a c\u00f4ng ty, ELVN-001, \u0111\u00e3 ch\u1ee9ng minh t\u1ef7 l\u1ec7 <strong>\u0111\u00e1p \u1ee9ng ph\u00e2n t\u1eed ch\u00ednh 47%<\/strong> \u1ea5n t\u01b0\u1ee3ng \u1edf b\u1ec7nh nh\u00e2n b\u1ea1ch c\u1ea7u t\u1ee7y m\u1ea1n t\u00ednh giai \u0111o\u1ea1n mu\u1ed9n \u0111\u00e3 c\u1ea1n ki\u1ec7t c\u00e1c l\u1ef1a ch\u1ecdn \u0111i\u1ec1u tr\u1ecb kh\u00e1c (<a href=\"https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-announces-updated-positive-data-from-phase-1-clinical-trial-of-elvn-001-in-cml-at-eha-2025-congress-302481050.html\">K\u1ebft qu\u1ea3 Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng<\/a>).<\/p> <p>\u0110i\u1ec1u l\u00e0m Enliven \u0111\u1eb7c bi\u1ec7t th\u00fa v\u1ecb l\u00e0 chi\u1ebfn l\u01b0\u1ee3c t\u1eadp trung v\u00e0o <strong>b\u1ec7nh nh\u00e2n kh\u00e1ng \u0111i\u1ec1u tr\u1ecb<\/strong> \u2014 nh\u1eefng ng\u01b0\u1eddi \u0111\u00e3 th\u1ea5t b\u1ea1i v\u1edbi c\u00e1c li\u1ec7u ph\u00e1p m\u1edbi h\u01a1n nh\u01b0 Scemblix c\u1ee7a Novartis. C\u00e1ch ti\u1ebfp c\u1eadn n\u00e0y nh\u1eafm v\u00e0o m\u1ed9t nh\u00f3m b\u1ec7nh nh\u00e2n c\u00f3 nhu c\u1ea7u cao v\u00e0 c\u00f3 th\u1ec3 \u0111\u1ecbnh gi\u00e1 cao n\u1ebfu th\u00e0nh c\u00f4ng.<\/p> <p>C\u00f4ng ty \u0111\u1eb7t tr\u1ee5 s\u1edf t\u1ea1i Boulder, Colorado, v\u1edbi kho\u1ea3ng 65 nh\u00e2n vi\u00ean chuy\u00ean t\u00e2m ph\u00e1t tri\u1ec3n pipeline. M\u00f4 h\u00ecnh kinh doanh c\u1ee7a h\u1ecd t\u1eadp trung v\u00e0o ph\u00e1t tri\u1ec3n c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf ph\u00e2n t\u1eed nh\u1ecf ch\u1ecdn l\u1ecdc cao, mang l\u1ea1i h\u1ed3 s\u01a1 an to\u00e0n c\u1ea3i thi\u1ec7n v\u00e0 k\u1ebft qu\u1ea3 b\u1ec7nh nh\u00e2n t\u1ed1t h\u01a1n so v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb hi\u1ec7n c\u00f3.<\/p> <p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb cho n\u0103m 2025<\/strong>: Vi\u1ec7c huy \u0111\u1ed9ng th\u00e0nh c\u00f4ng 200 tri\u1ec7u USD v\u1ed1n c\u1ed5 ph\u1ea7n sau d\u1eef li\u1ec7u l\u00e2m s\u00e0ng t\u00edch c\u1ef1c kh\u00f4ng ch\u1ec9 l\u00e0 v\u1ec1 t\u00e0i ch\u00ednh \u2014 n\u00f3 c\u00f2n \u0111\u1ea1i di\u1ec7n cho m\u1ed9t trong nh\u1eefng kho\u1ea3n \u0111\u1ea7u t\u01b0 \u0111\u01a1n l\u1ebb l\u1edbn nh\u1ea5t trong ch\u01b0\u01a1ng tr\u00ecnh \u0111i\u1ec1u tr\u1ecb CML giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u0103m nay, th\u1ec3 hi\u1ec7n ni\u1ec1m tin m\u1ea1nh m\u1ebd c\u1ee7a c\u00e1c t\u1ed5 ch\u1ee9c v\u00e0o chi\u1ebfn l\u01b0\u1ee3c ch\u1ed1ng l\u1ea1i kh\u00e1ng thu\u1ed1c c\u1ee7a h\u1ecd.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Ph\u00e2n T\u00edch C\u1ed5 Phi\u1ebfu Enliven Therapeutics: T\u00ecnh Tr\u1ea1ng Hi\u1ec7n T\u1ea1i v\u00e0 Ti\u1ec1m N\u0103ng T\u01b0\u01a1ng Lai<\/h2>\n<p><strong>T\u00ednh \u0111\u1ebfn ng\u00e0y 31 th\u00e1ng 8 n\u0103m 2025, c\u1ed5 phi\u1ebfu Enliven Therapeutics (ELVN) giao d\u1ecbch \u1edf m\u1ee9c 20,68 USD\/c\u1ed5 phi\u1ebfu<\/strong> tr\u00ean s\u00e0n NASDAQ. C\u1ed5 phi\u1ebfu \u0111\u00e3 tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 trong su\u1ed1t n\u0103m 2025, giao d\u1ecbch trong ph\u1ea1m vi 52 tu\u1ea7n t\u1eeb 13,30 USD \u0111\u1ebfn 30,03 USD, th\u1ec3 hi\u1ec7n c\u1ea3 r\u1ee7i ro v\u00e0 c\u01a1 h\u1ed9i l\u1edbn cho nh\u00e0 \u0111\u1ea7u t\u01b0.<\/p>\n<p>H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch: <strong>Ng\u00e0y 12 th\u00e1ng 11 n\u0103m 2025<\/strong> l\u00e0 ng\u00e0y c\u1ef1c k\u1ef3 quan tr\u1ecdng \u0111\u1ed1i v\u1edbi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ELVN. \u0110\u00e2y l\u00e0 th\u1eddi \u0111i\u1ec3m c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn qu\u00fd 3, v\u00e0 c\u00e1c m\u00f4 h\u00ecnh l\u1ecbch s\u1eed cho th\u1ea5y \u0111i\u1ec1u n\u00e0y c\u00f3 th\u1ec3 k\u00edch ho\u1ea1t nh\u1eefng bi\u1ebfn \u0111\u1ed9ng gi\u00e1 l\u1edbn.<\/p>\n<h3>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng L\u1ee3i Nhu\u1eadn L\u1ecbch S\u1eed<\/h3>\n<p>Xem x\u00e9t hi\u1ec7u su\u1ea5t g\u1ea7n \u0111\u00e2y quanh c\u00e1c s\u1ef1 ki\u1ec7n ch\u00ednh cung c\u1ea5p nh\u1eefng hi\u1ec3u bi\u1ebft gi\u00e1 tr\u1ecb:<\/p>\n<p><strong>Ng\u00e0y 13 th\u00e1ng 8 n\u0103m 2025<\/strong> &#8211; C\u00f4ng b\u1ed1 l\u1ee3i nhu\u1eadn qu\u00fd 2: ELVN b\u00e1o c\u00e1o k\u1ebft qu\u1ea3 t\u1ed1t h\u01a1n k\u1ef3 v\u1ecdng v\u1edbi EPS l\u00e0 -0,49 USD so v\u1edbi \u01b0\u1edbc t\u00ednh \u0111\u1ed3ng thu\u1eadn -0,53 USD (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/ELVN\/earnings\/\">D\u1eef li\u1ec7u L\u1ee3i Nhu\u1eadn MarketBeat<\/a>). B\u1ea5t ng\u1edd t\u00edch c\u1ef1c n\u00e0y cho th\u1ea5y kh\u1ea3 n\u0103ng qu\u1ea3n l\u00fd chi ph\u00ed trong khi ti\u1ebfn tri\u1ec3n c\u00e1c ch\u01b0\u01a1ng tr\u00ecnh l\u00e2m s\u00e0ng c\u1ee7a c\u00f4ng ty.<\/p>\n<p>Ph\u1ea3n \u1ee9ng c\u1ee7a c\u1ed5 phi\u1ebfu v\u1edbi tin t\u1ee9c n\u00e0y r\u1ea5t \u0111\u00e1ng ch\u00fa \u00fd \u2014 trong khi nhi\u1ec1u c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ch\u1ee9ng ki\u1ebfn bi\u1ebfn \u0111\u1ed9ng m\u1ea1nh v\u00e0o ng\u00e0y c\u00f4ng b\u1ed1 l\u1ee3i nhu\u1eadn, ELVN th\u1ec3 hi\u1ec7n s\u1ef1 \u1ed5n \u0111\u1ecbnh t\u01b0\u01a1ng \u0111\u1ed1i, cho th\u1ea5y c\u01a1 s\u1edf nh\u00e0 \u0111\u1ea7u t\u01b0 tr\u01b0\u1edfng th\u00e0nh hi\u1ec3u r\u00f5 v\u1ec1 ti\u1ebfn tr\u00ecnh ph\u00e1t tri\u1ec3n d\u00e0i h\u1ea1n.<\/p>\n<h3>H\u00e0nh Tr\u00ecnh Gi\u00e1 S\u00e1u Th\u00e1ng (Th\u00e1ng 3 &#8211; Th\u00e1ng 8 n\u0103m 2025)<\/h3>\n<p>ELVN \u0111\u00e3 v\u01b0\u1ee3t qua m\u1ed9t con \u0111\u01b0\u1eddng \u0111\u1ea7y th\u1eed th\u00e1ch nh\u01b0ng \u0111\u1ea7y h\u1ee9a h\u1eb9n trong s\u00e1u th\u00e1ng qua:<\/p>\n<table>\n<thead>\n<tr>\n<th>Th\u00e1ng<\/th>\n<th>S\u1ef1 Ki\u1ec7n Ch\u00ednh<\/th>\n<th>Ph\u1ea1m Vi Gi\u00e1<\/th>\n<th>Xu H\u01b0\u1edbng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Th\u00e1ng 3 n\u0103m 2025<\/td>\n<td>L\u1ea1c quan d\u1eef li\u1ec7u l\u00e2m s\u00e0ng ban \u0111\u1ea7u<\/td>\n<td>25-28 USD<\/td>\n<td>\u2197\ufe0f \u0110\u00e0 t\u0103ng<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 4 n\u0103m 2025<\/td>\n<td>\u00c1p l\u1ef1c r\u1ed9ng h\u01a1n t\u1eeb ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/td>\n<td>18-22 USD<\/td>\n<td>\u2198\ufe0f \u0110i\u1ec1u ch\u1ec9nh to\u00e0n ng\u00e0nh<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 5 n\u0103m 2025<\/td>\n<td>Chu\u1ea9n b\u1ecb thuy\u1ebft tr\u00ecnh h\u1ed9i ngh\u1ecb<\/td>\n<td>20-24 USD<\/td>\n<td>\u27a1\ufe0f T\u00edch l\u0169y<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 6 n\u0103m 2025<\/td>\n<td>C\u00f4ng b\u1ed1 d\u1eef li\u1ec7u t\u1ea1i H\u1ed9i ngh\u1ecb EHA<\/td>\n<td>22-27 USD<\/td>\n<td>\u2197\ufe0f Ph\u1ea3n \u1ee9ng t\u00edch c\u1ef1c m\u1ea1nh m\u1ebd<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 7 n\u0103m 2025<\/td>\n<td>Ch\u1ed1t l\u1eddi sau h\u1ed9i ngh\u1ecb<\/td>\n<td>19-23 USD<\/td>\n<td>\u2198\ufe0f \u0110i\u1ec1u ch\u1ec9nh l\u00e0nh m\u1ea1nh<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 8 n\u0103m 2025<\/td>\n<td>L\u1ee3i nhu\u1eadn qu\u00fd 2 v\u00e0 h\u1ebft h\u1ea1n th\u1eddi gian kh\u00f3a c\u1ed5 phi\u1ebfu<\/td>\n<td>20-21 USD<\/td>\n<td>\u27a1\ufe0f \u1ed4n \u0111\u1ecbnh gi\u1eefa c\u00e1c s\u1ef1 ki\u1ec7n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>T\u0103ng 11% c\u1ed5 phi\u1ebfu sau d\u1eef li\u1ec7u t\u00edch c\u1ef1c ELVN-001<\/strong> t\u1ea1i h\u1ed9i ngh\u1ecb Hi\u1ec7p h\u1ed9i Huy\u1ebft h\u1ecdc Ch\u00e2u \u00c2u (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">B\u00e1o c\u00e1o Oncology Pipeline<\/a>) cho th\u1ea5y c\u00e1c c\u1ed9t m\u1ed1c l\u00e2m s\u00e0ng th\u00fac \u0111\u1ea9y \u0111\u1ecbnh gi\u00e1 trong ng\u00e0nh n\u00e0y nh\u01b0 th\u1ebf n\u00e0o.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2>\n<p>D\u1ef1a tr\u00ean \u0111\u1ed3ng thu\u1eadn hi\u1ec7n t\u1ea1i c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u00e0 ti\u1ebfn tri\u1ec3n l\u00e2m s\u00e0ng, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 mong \u0111\u1ee3i:<\/p>\n<p><strong>M\u1ee5c ti\u00eau cu\u1ed1i n\u0103m 2025: 25-30 USD<\/strong> &#8211; D\u00f2ng d\u1eef li\u1ec7u t\u00edch c\u1ef1c ti\u1ebfp t\u1ee5c t\u1eeb c\u00e1c th\u1eed nghi\u1ec7m \u0111ang di\u1ec5n ra c\u00f3 th\u1ec3 \u0111\u1ea9y ELVN v\u1ec1 ph\u00eda cu\u1ed1i tr\u00ean c\u1ee7a ph\u1ea1m vi giao d\u1ecbch g\u1ea7n \u0111\u00e2y. B\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn th\u00e1ng 11 s\u1ebd r\u1ea5t quan tr\u1ecdng \u0111\u1ec3 thi\u1ebft l\u1eadp \u0111\u00e0 t\u0103ng cu\u1ed1i n\u0103m.<\/p>\n<p><strong>D\u1ef1 b\u00e1o n\u0103m 2026: 35-45 USD<\/strong> &#8211; N\u1ebfu c\u00e1c th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 2 b\u1eaft \u0111\u1ea7u th\u00e0nh c\u00f4ng v\u00e0 c\u00e1c con \u0111\u01b0\u1eddng ph\u00e1p l\u00fd \u0111\u01b0\u1ee3c th\u00f4ng qua, ELVN c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c \u0111\u1ecbnh gi\u00e1 l\u1ea1i \u0111\u00e1ng k\u1ec3 khi th\u1ecb tr\u01b0\u1eddng \u0111\u00e1nh gi\u00e1 r\u1ee7i ro l\u00e2m s\u00e0ng gi\u1ea3m.<\/p>\n<p><strong>D\u1ef1 \u0111o\u00e1n n\u0103m 2028: 50-70 USD<\/strong> &#8211; C\u00e1c \u0111\u1ec7 tr\u00ecnh ph\u00e1p l\u00fd ti\u1ec1m n\u0103ng v\u00e0 th\u1ea3o lu\u1eadn h\u1ee3p t\u00e1c c\u00f3 th\u1ec3 th\u00fac \u0111\u1ea9y \u0111\u1ecbnh gi\u00e1 h\u01b0\u1edbng t\u1edbi c\u00e1c m\u1ee5c ti\u00eau gi\u00e1 c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch tr\u00ean 50 USD.<\/p>\n<p><strong>T\u1ea7m nh\u00ecn n\u0103m 2030: 80-100+ USD<\/strong> &#8211; Th\u01b0\u01a1ng m\u1ea1i h\u00f3a th\u00e0nh c\u00f4ng v\u00e0 th\u00e2m nh\u1eadp th\u1ecb tr\u01b0\u1eddng c\u00f3 th\u1ec3 thi\u1ebft l\u1eadp ELVN nh\u01b0 m\u1ed9t c\u00f4ng ty t\u1ef7 \u0111\u00f4, m\u1eb7c d\u00f9 \u0111i\u1ec1u n\u00e0y ho\u00e0n to\u00e0n ph\u1ee5 thu\u1ed9c v\u00e0o th\u00e0nh c\u00f4ng l\u00e2m s\u00e0ng v\u00e0 ph\u00ea duy\u1ec7t ph\u00e1p l\u00fd.<\/p>\n<p><strong>K\u1ebft lu\u1eadn: MUA M\u1ea0NH<\/strong> d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 ch\u1ecbu r\u1ee7i ro v\u1edbi t\u1ea7m nh\u00ecn 3-5 n\u0103m. \u0110\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 trung b\u00ecnh 41,20 USD (<a href=\"https:\/\/stockanalysis.com\/stocks\/elvn\/forecast\/\">Ph\u00e2n t\u00edch C\u1ed5 phi\u1ebfu<\/a>) \u0111\u1ea1i di\u1ec7n cho ti\u1ec1m n\u0103ng t\u0103ng h\u01a1n 100% so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i.<\/p>\n<h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2>\n<h3>R\u1ee7i Ro M\u1ecdi Nh\u00e0 \u0110\u1ea7u T\u01b0 Ph\u1ea3i C\u00e2n Nh\u1eafc<\/h3>\n<ul>\n<li><strong>R\u1ee7i ro Th\u1ea5t b\u1ea1i Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng<\/strong> &#8211; Kho\u1ea3ng 60% c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc tr\u1ea3i qua s\u1ee5t gi\u1ea3m tr\u00ean 50% khi c\u00f3 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m ti\u00eau c\u1ef1c. To\u00e0n b\u1ed9 \u0111\u1ecbnh gi\u00e1 c\u1ee7a ELVN ph\u1ee5 thu\u1ed9c v\u00e0o th\u00e0nh c\u00f4ng c\u1ee7a ELVN-001.<\/li>\n<li><strong>Tr\u00ec ho\u00e3n Ph\u00ea duy\u1ec7t Ph\u00e1p l\u00fd<\/strong> &#8211; Qu\u00e1 tr\u00ecnh xem x\u00e9t c\u1ee7a FDA c\u00f3 th\u1ec3 k\u00e9o d\u00e0i 6-12 th\u00e1ng b\u1ea5t ng\u1edd, l\u00e0m \u0111\u00f3ng b\u0103ng l\u1ee3i nhu\u1eadn ti\u1ec1m n\u0103ng v\u00e0 t\u1ea1o ra s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn.<\/li>\n<li><strong>Lo ng\u1ea1i v\u1ec1 D\u00f2ng ti\u1ec1n Ti\u00eau hao<\/strong> &#8211; M\u1eb7c d\u00f9 v\u1eeba huy \u0111\u1ed9ng \u0111\u01b0\u1ee3c 200 tri\u1ec7u USD (<a href=\"https:\/\/www.oncologypipeline.com\/apexonco\/eha-2025-elvn-001-enlivens-investors\">Chi ti\u1ebft Huy \u0111\u1ed9ng V\u1ed1n<\/a>), d\u00f2ng ti\u1ec1n \u00e2m 52,7 tri\u1ec7u USD c\u1ee7a c\u00f4ng ty c\u1ea7n \u0111\u01b0\u1ee3c theo d\u00f5i ch\u1eb7t ch\u1ebd.<\/li>\n<li><strong>Bi\u1ebfn \u0111\u1ed9ng Cao<\/strong> &#8211; V\u1edbi bi\u1ebfn \u0111\u1ed9ng trung b\u00ecnh h\u00e0ng ng\u00e0y 4,37% v\u00e0 t\u1ef7 l\u1ec7 s\u1edf h\u1eefu t\u1ed5 ch\u1ee9c 95%, c\u00e1c giao d\u1ecbch l\u1edbn c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng m\u1ea1nh \u0111\u1ebfn gi\u00e1 c\u1ed5 phi\u1ebfu.<\/li>\n<\/ul>\n<h3>T\u00edn Hi\u1ec7u Xanh Cho \u0110\u1ea7u T\u01b0 N\u0103m 2025<\/h3>\n<ul>\n<li><strong>D\u1eef li\u1ec7u L\u00e2m s\u00e0ng \u0110\u1ed9t ph\u00e1<\/strong> &#8211; ELVN-001 cho th\u1ea5y t\u1ef7 l\u1ec7 \u0111\u00e1p \u1ee9ng ph\u00e2n t\u1eed ch\u00ednh 47% \u1edf b\u1ec7nh nh\u00e2n CML \u0111\u00e3 \u0111i\u1ec1u tr\u1ecb nhi\u1ec1u l\u1ea7n, c\u1ea1nh tranh v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb nh\u01b0 Scemblix c\u1ee7a Novartis.<\/li>\n<li><strong>Huy \u0111\u1ed9ng V\u1ed1n Th\u00e0nh c\u00f4ng<\/strong> &#8211; Vi\u1ec7c m\u1edf r\u1ed9ng v\u1ed1n 200 tri\u1ec7u USD cung c\u1ea5p ngu\u1ed3n l\u1ef1c \u0111\u1ebfn n\u0103m 2029, gi\u1ea3m b\u1edbt lo ng\u1ea1i pha lo\u00e3ng g\u1ea7n h\u1ea1n.<\/li>\n<li><strong>Ni\u1ec1m Tin c\u1ee7a Nh\u00e0 Ph\u00e2n t\u00edch<\/strong> &#8211; T\u1ea5t c\u1ea3 5 nh\u00e0 ph\u00e2n t\u00edch theo d\u00f5i duy tr\u00ec \u0111\u00e1nh gi\u00e1 &#8220;Mua M\u1ea1nh&#8221; v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 l\u00ean \u0111\u1ebfn 52 USD.<\/li>\n<li><strong>Nhu c\u1ea7u Th\u1ecb tr\u01b0\u1eddng<\/strong> &#8211; CML l\u00e0 th\u1ecb tr\u01b0\u1eddng h\u01a1n 7 t\u1ef7 USD v\u1edbi nhu c\u1ea7u ch\u01b0a \u0111\u01b0\u1ee3c \u0111\u00e1p \u1ee9ng l\u1edbn \u1edf b\u1ec7nh nh\u00e2n kh\u00e1ng \u0111i\u1ec1u tr\u1ecb.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2>\n<ol>\n<li><strong>B\u1eaft \u0111\u1ea7u Nh\u1ecf<\/strong> &#8211; Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 5% danh m\u1ee5c cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ee7i ro cao nh\u01b0 ELVN. Ph\u1ea7n th\u01b0\u1edfng ti\u1ec1m n\u0103ng l\u1edbn, nh\u01b0ng r\u1ee7i ro c\u0169ng kh\u00f4ng nh\u1ecf.<\/li>\n<li><strong>Trung B\u00ecnh Gi\u00e1 Mua<\/strong> &#8211; Thay v\u00ec mua m\u1ed9t l\u1ea7n l\u1edbn, h\u00e3y c\u00e2n nh\u1eafc mua t\u1eebng ph\u1ea7n nh\u1ecf trong v\u00e0i tu\u1ea7n \u0111\u1ec3 trung b\u00ecnh gi\u00e1 v\u00e0o.<\/li>\n<li><strong>\u0110\u1eb7t C\u1ea3nh B\u00e1o cho Ng\u00e0y 12 Th\u00e1ng 11<\/strong> &#8211; \u0110\u00e1nh d\u1ea5u l\u1ecbch cho b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn qu\u00fd 3 v\u00e0 chu\u1ea9n b\u1ecb cho bi\u1ebfn \u0111\u1ed9ng c\u00f3 th\u1ec3 x\u1ea3y ra quanh s\u1ef1 ki\u1ec7n n\u00e0y.<\/li>\n<li><strong>Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc d\u00e0nh cho nh\u00e0 giao d\u1ecbch<\/strong>: &#8220;\u0110\u1ea7u t\u01b0 v\u00e0o c\u00f4ng ngh\u1ec7 sinh h\u1ecdc gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2 th\u1eddi trung h\u1ecdc \u2014 90% l\u00e0 drama, 10% l\u00e0 ti\u1ebfn tri\u1ec3n th\u1ef1c s\u1ef1, nh\u01b0ng 10% \u0111\u00f3 c\u00f3 th\u1ec3 thay \u0111\u1ed5i cu\u1ed9c \u0111\u1eddi khi n\u00f3 th\u00e0nh c\u00f4ng!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) &#8211; T\u1eebng B\u01b0\u1edbc<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0110\u1ed9ng<\/th>\n<th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ch\u1ecdn N\u1ec1n T\u1ea3ng Giao D\u1ecbch<\/td>\n<td>Ch\u1ecdn nh\u00e0 m\u00f4i gi\u1edbi cung c\u1ea5p truy c\u1eadp NASDAQ v\u00e0 ph\u00ed c\u1ea1nh tranh cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Ho\u00e0n Th\u00e0nh N\u1ea1p Ti\u1ec1n T\u00e0i Kho\u1ea3n<\/td>\n<td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i r\u1ee7i ro \u2014 ngay c\u1ea3 100 USD c\u0169ng c\u00f3 th\u1ec3 gi\u00fap b\u1ea1n b\u1eaft \u0111\u1ea7u<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>T\u00ecm ki\u1ebfm &#8220;ELVN&#8221;<\/td>\n<td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n ch\u00ednh x\u00e1c, kh\u00f4ng ch\u1ec9 t\u00ean c\u00f4ng ty<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Ch\u1ecdn Lo\u1ea1i L\u1ec7nh<\/td>\n<td>S\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o thay v\u00ec l\u1ec7nh th\u1ecb tr\u01b0\u1eddng<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Xem l\u1ea1i v\u00e0 X\u00e1c nh\u1eadn<\/td>\n<td>Ki\u1ec3m tra k\u1ef9 chi ti\u1ebft l\u1ec7nh v\u00e0 hi\u1ec3u c\u00e1c chi ph\u00ed hoa h\u1ed3ng<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Thu H\u00fat Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0 v\u1edbi c\u00e1c c\u00f4ng ty nh\u01b0 Enliven Therapeutics, Pocket Option cung c\u1ea5p nhi\u1ec1u l\u1ee3i th\u1ebf gi\u00fap vi\u1ec7c tham gia th\u1ecb tr\u01b0\u1eddng tr\u1edf n\u00ean d\u1ec5 d\u00e0ng h\u01a1n:<\/p>\n<ul>\n<li><strong>S\u1ed1 ti\u1ec1n g\u1eedi t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> &#8211; R\u00e0o c\u1ea3n c\u1ef1c th\u1ea5p n\u00e0y cho ph\u00e9p nh\u00e0 \u0111\u1ea7u t\u01b0 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u00e0 t\u00edch l\u0169y kinh nghi\u1ec7m m\u00e0 kh\u00f4ng c\u1ea7n cam k\u1ebft t\u00e0i ch\u00ednh l\u1edbn.<\/li>\n<li><strong>Quy tr\u00ecnh x\u00e1c minh nhanh ch\u00f3ng<\/strong> &#8211; Quy tr\u00ecnh KYC (Bi\u1ebft Kh\u00e1ch H\u00e0ng) ch\u1ec9 m\u1ea5t 1 ph\u00fat v\u1edbi b\u1ea5t k\u1ef3 gi\u1ea5y t\u1edd t\u00f9y th\u00e2n n\u00e0o, gi\u00fap b\u1ea1n c\u00f3 th\u1ec3 b\u1eaft \u0111\u1ea7u giao d\u1ecbch g\u1ea7n nh\u01b0 ngay l\u1eadp t\u1ee9c sau khi \u0111\u0103ng k\u00fd.<\/li>\n<li><strong>Nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> &#8211; V\u1edbi h\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n bao g\u1ed3m ti\u1ec1n \u0111i\u1ec7n t\u1eed, v\u00ed \u0111i\u1ec7n t\u1eed v\u00e0 c\u00e1c l\u1ef1a ch\u1ecdn ng\u00e2n h\u00e0ng truy\u1ec1n th\u1ed1ng, vi\u1ec7c ti\u1ebfp c\u1eadn l\u1ee3i nhu\u1eadn c\u1ee7a b\u1ea1n tr\u1edf n\u00ean thu\u1eadn ti\u1ec7n v\u00e0 linh ho\u1ea1t.<\/li>\n<\/ul>\n<p>Nh\u1eefng t\u00ednh n\u0103ng n\u00e0y l\u00e0m cho Pocket Option \u0111\u1eb7c bi\u1ec7t ph\u00f9 h\u1ee3p v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n th\u1eed s\u1ee9c v\u1edbi \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc m\u00e0 kh\u00f4ng b\u1ecb ph\u1ee9c t\u1ea1p hay chi ph\u00ed ban \u0111\u1ea7u cao.<\/p>\n<h2>\ud83c\udf0d Enliven Therapeutics n\u0103m 2025: Ti\u00ean Phong Ung Th\u01b0 H\u1ecdc Ch\u00ednh X\u00e1c<\/h2>\n<p>Enliven Therapeutics \u0111\u1ee9ng \u1edf v\u1ecb tr\u00ed ti\u00ean phong trong ung th\u01b0 h\u1ecdc ch\u00ednh x\u00e1c v\u1edbi c\u00e1ch ti\u1ebfp c\u1eadn t\u1eadp trung v\u00e0o ph\u00e1t tri\u1ec3n ch\u1ea5t \u1ee9c ch\u1ebf kinase. \u1ee8ng vi\u00ean h\u00e0ng \u0111\u1ea7u c\u1ee7a c\u00f4ng ty, ELVN-001, \u0111\u00e3 ch\u1ee9ng minh t\u1ef7 l\u1ec7 <strong>\u0111\u00e1p \u1ee9ng ph\u00e2n t\u1eed ch\u00ednh 47%<\/strong> \u1ea5n t\u01b0\u1ee3ng \u1edf b\u1ec7nh nh\u00e2n b\u1ea1ch c\u1ea7u t\u1ee7y m\u1ea1n t\u00ednh giai \u0111o\u1ea1n mu\u1ed9n \u0111\u00e3 c\u1ea1n ki\u1ec7t c\u00e1c l\u1ef1a ch\u1ecdn \u0111i\u1ec1u tr\u1ecb kh\u00e1c (<a href=\"https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-announces-updated-positive-data-from-phase-1-clinical-trial-of-elvn-001-in-cml-at-eha-2025-congress-302481050.html\">K\u1ebft qu\u1ea3 Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng<\/a>).<\/p>\n<p>\u0110i\u1ec1u l\u00e0m Enliven \u0111\u1eb7c bi\u1ec7t th\u00fa v\u1ecb l\u00e0 chi\u1ebfn l\u01b0\u1ee3c t\u1eadp trung v\u00e0o <strong>b\u1ec7nh nh\u00e2n kh\u00e1ng \u0111i\u1ec1u tr\u1ecb<\/strong> \u2014 nh\u1eefng ng\u01b0\u1eddi \u0111\u00e3 th\u1ea5t b\u1ea1i v\u1edbi c\u00e1c li\u1ec7u ph\u00e1p m\u1edbi h\u01a1n nh\u01b0 Scemblix c\u1ee7a Novartis. C\u00e1ch ti\u1ebfp c\u1eadn n\u00e0y nh\u1eafm v\u00e0o m\u1ed9t nh\u00f3m b\u1ec7nh nh\u00e2n c\u00f3 nhu c\u1ea7u cao v\u00e0 c\u00f3 th\u1ec3 \u0111\u1ecbnh gi\u00e1 cao n\u1ebfu th\u00e0nh c\u00f4ng.<\/p>\n<p>C\u00f4ng ty \u0111\u1eb7t tr\u1ee5 s\u1edf t\u1ea1i Boulder, Colorado, v\u1edbi kho\u1ea3ng 65 nh\u00e2n vi\u00ean chuy\u00ean t\u00e2m ph\u00e1t tri\u1ec3n pipeline. M\u00f4 h\u00ecnh kinh doanh c\u1ee7a h\u1ecd t\u1eadp trung v\u00e0o ph\u00e1t tri\u1ec3n c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf ph\u00e2n t\u1eed nh\u1ecf ch\u1ecdn l\u1ecdc cao, mang l\u1ea1i h\u1ed3 s\u01a1 an to\u00e0n c\u1ea3i thi\u1ec7n v\u00e0 k\u1ebft qu\u1ea3 b\u1ec7nh nh\u00e2n t\u1ed1t h\u01a1n so v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb hi\u1ec7n c\u00f3.<\/p>\n<p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb cho n\u0103m 2025<\/strong>: Vi\u1ec7c huy \u0111\u1ed9ng th\u00e0nh c\u00f4ng 200 tri\u1ec7u USD v\u1ed1n c\u1ed5 ph\u1ea7n sau d\u1eef li\u1ec7u l\u00e2m s\u00e0ng t\u00edch c\u1ef1c kh\u00f4ng ch\u1ec9 l\u00e0 v\u1ec1 t\u00e0i ch\u00ednh \u2014 n\u00f3 c\u00f2n \u0111\u1ea1i di\u1ec7n cho m\u1ed9t trong nh\u1eefng kho\u1ea3n \u0111\u1ea7u t\u01b0 \u0111\u01a1n l\u1ebb l\u1edbn nh\u1ea5t trong ch\u01b0\u01a1ng tr\u00ecnh \u0111i\u1ec1u tr\u1ecb CML giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u0103m nay, th\u1ec3 hi\u1ec7n ni\u1ec1m tin m\u1ea1nh m\u1ebd c\u1ee7a c\u00e1c t\u1ed5 ch\u1ee9c v\u00e0o chi\u1ebfn l\u01b0\u1ee3c ch\u1ed1ng l\u1ea1i kh\u00e1ng thu\u1ed1c c\u1ee7a h\u1ecd.<\/p>\n"},"faq":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu Enliven Therapeutics (ELVN)?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu ELVN th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch ch\u1ee9ng kho\u00e1n c\u00f3 truy c\u1eadp s\u00e0n NASDAQ. Ch\u1ecdn nh\u00e0 m\u00f4i gi\u1edbi uy t\u00edn, n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n, t\u00ecm m\u00e3 c\u1ed5 phi\u1ebfu ELVN, ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 x\u00e1c nh\u1eadn giao d\u1ecbch."},{"question":"R\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Enliven Therapeutics l\u00e0 g\u00ec?","answer":"R\u1ee7i ro l\u1edbn nh\u1ea5t l\u00e0 th\u1ea5t b\u1ea1i trong th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng ELVN-001, tr\u00ec ho\u00e3n ph\u00ea duy\u1ec7t ph\u00e1p l\u00fd, d\u00f2ng ti\u1ec1n ti\u00eau hao \u00e2m v\u00e0 bi\u1ebfn \u0111\u1ed9ng gi\u00e1 cao do t\u00ednh ch\u1ea5t ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu ELVN trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 b\u00e1o gi\u00e1 ELVN c\u00f3 th\u1ec3 \u0111\u1ea1t 25-30 USD v\u00e0o cu\u1ed1i n\u0103m 2025, 35-45 USD n\u0103m 2026, 50-70 USD n\u0103m 2028 v\u00e0 80-100+ USD v\u00e0o n\u0103m 2030 n\u1ebfu c\u00e1c th\u1eed nghi\u1ec7m v\u00e0 ph\u00ea duy\u1ec7t th\u00e0nh c\u00f4ng."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 v\u00e0o ELVN?","answer":"Pocket Option c\u00f3 s\u1ed1 ti\u1ec1n g\u1eedi t\u1ed1i thi\u1ec3u th\u1ea5p, quy tr\u00ecnh x\u00e1c minh nhanh, nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n v\u00e0 giao di\u1ec7n th\u00e2n thi\u1ec7n, ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi b\u1eaft \u0111\u1ea7u."},{"question":"Enliven Therapeutics t\u1eadp trung v\u00e0o \u0111i\u1ec1u tr\u1ecb b\u1ec7nh g\u00ec?","answer":"Enliven Therapeutics t\u1eadp trung ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb b\u1ec7nh b\u1ea1ch c\u1ea7u t\u1ee7y m\u1ea1n t\u00ednh (CML), \u0111\u1eb7c bi\u1ec7t l\u00e0 cho nh\u1eefng b\u1ec7nh nh\u00e2n kh\u00e1ng \u0111i\u1ec1u tr\u1ecb v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p hi\u1ec7n c\u00f3."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu Enliven Therapeutics (ELVN)?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu ELVN th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch ch\u1ee9ng kho\u00e1n c\u00f3 truy c\u1eadp s\u00e0n NASDAQ. Ch\u1ecdn nh\u00e0 m\u00f4i gi\u1edbi uy t\u00edn, n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n, t\u00ecm m\u00e3 c\u1ed5 phi\u1ebfu ELVN, ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 x\u00e1c nh\u1eadn giao d\u1ecbch."},{"question":"R\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Enliven Therapeutics l\u00e0 g\u00ec?","answer":"R\u1ee7i ro l\u1edbn nh\u1ea5t l\u00e0 th\u1ea5t b\u1ea1i trong th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng ELVN-001, tr\u00ec ho\u00e3n ph\u00ea duy\u1ec7t ph\u00e1p l\u00fd, d\u00f2ng ti\u1ec1n ti\u00eau hao \u00e2m v\u00e0 bi\u1ebfn \u0111\u1ed9ng gi\u00e1 cao do t\u00ednh ch\u1ea5t ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu ELVN trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 b\u00e1o gi\u00e1 ELVN c\u00f3 th\u1ec3 \u0111\u1ea1t 25-30 USD v\u00e0o cu\u1ed1i n\u0103m 2025, 35-45 USD n\u0103m 2026, 50-70 USD n\u0103m 2028 v\u00e0 80-100+ USD v\u00e0o n\u0103m 2030 n\u1ebfu c\u00e1c th\u1eed nghi\u1ec7m v\u00e0 ph\u00ea duy\u1ec7t th\u00e0nh c\u00f4ng."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 v\u00e0o ELVN?","answer":"Pocket Option c\u00f3 s\u1ed1 ti\u1ec1n g\u1eedi t\u1ed1i thi\u1ec3u th\u1ea5p, quy tr\u00ecnh x\u00e1c minh nhanh, nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n v\u00e0 giao di\u1ec7n th\u00e2n thi\u1ec7n, ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi b\u1eaft \u0111\u1ea7u."},{"question":"Enliven Therapeutics t\u1eadp trung v\u00e0o \u0111i\u1ec1u tr\u1ecb b\u1ec7nh g\u00ec?","answer":"Enliven Therapeutics t\u1eadp trung ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb b\u1ec7nh b\u1ea1ch c\u1ea7u t\u1ee7y m\u1ea1n t\u00ednh (CML), \u0111\u1eb7c bi\u1ec7t l\u00e0 cho nh\u1eefng b\u1ec7nh nh\u00e2n kh\u00e1ng \u0111i\u1ec1u tr\u1ecb v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p hi\u1ec7n c\u00f3."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-31T11:01:01+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)\",\"datePublished\":\"2025-08-31T11:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"datePublished\":\"2025-08-31T11:01:01+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-31T11:01:01+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)","datePublished":"2025-08-31T11:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","datePublished":"2025-08-31T11:01:01+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals6.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enliven Therapeutics, Inc. (ELVN)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":363837,"slug":"how-to-buy-enliven-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Enliven Therapeutics, Inc. (ELVN) - Investimento em a\u00e7\u00f5es da Enliven Therapeutics, Inc. (ELVN)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-enliven-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/363841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=363841"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/363841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334036"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=363841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=363841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=363841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}